Amylyx Pharmaceuticals, Inc.
- AMLX
- NASDAQ
- Biotechnology
- ALS/Neurodegenerative Therapies
$27.33
Today +3.76%Quote Oct 19, 2026, 08:00 PM UTC
−22.39%over the last month
Max drawdown −22.4%From 1-month high −22.4%3 months +50.9%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Amylyx Pharmaceuticals
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
136
Market value
$3.05B
Quote Oct 19
Floor
$26.37
3.5% below price
Resistance
$27.59
1.0% above price
Price vs analyst targets
11 analysts
Lowest target
$42.00Highest target
$57.00
$42.00Highest target
$57.00
- Price $27.33
- Average target $52.20
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 91% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about AMLXPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free